Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 vaccine inactivated, Vero cell is an inactivated whole-virus COVID-19 vaccine produced using the Vero cell line derived from African green monkey kidney cells. The virus (typically CZ02 or 19nCoV-CDC-Tan-HB02 strain) is cultured on Vero cells, harvested, and then chemically inactivated (commonly with β-propiolactone). The resulting viral particles are purified and adsorbed onto aluminum hydroxide as an adjuvant. This formulation stimulates the immune system to produce neutralizing antibodies against SARS-CoV-2 without causing disease. It is indicated for active immunization to prevent COVID-19 and has been widely used globally under various brand names such as CoronaVac (Sinovac) and Covilo (Sinopharm). The primary indication is prevention of COVID-19 infection[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sars-cov-2 vaccine inactivated vero cell.